Stoke Therapeutics (STOK) Asset Writedowns and Impairment (2025)
Stoke Therapeutics' (STOK) quarterly Asset Writedowns and Impairment came in at $700000.0 in Q3 2025.
Stoke Therapeutics (STOK) Asset Writedowns and Impairment (2025) Analysis & Trends
Stoke Therapeutics' Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $700000.0 for Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 700,000.00 |
| Sep 30, 2025 | 700,000.00 |